APC and neoplasm: Intraperitoneal (150 mg/kg twice daily) and oral (300 mg/kg twice daily) administration of this drug in mouse xenografts with APC mutations that produce shorter protein forms resulted in 47.2% and 51.9% tumor growth inhibition, respectively.